1. Introduction {#s0005}
===============

Already in 1983 Syrjänen and colleagues published the first data suggesting that human papillomavirus (HPV) could be associated to a sub-group of head and neck squamous cell carcinoma (HNSCC) [@bib1]. Since then, the field of HPV, especially HPV type 16, in HNSCC has emerged considerably. Subsequently, in 2009, due to a large body of evidence the International Agency of Research of Cancer (IARC) declared that "there is a strong epidemiological evidence for the casual role of HPV16 in the aetiology of cancer of the oropharynx and tonsil" [@bib2]. Today, research on HPV and HNSCC in general has shifted and focuses on HPV in oropharyngeal squamous cell carcinoma (OPSCC). Moreover, recent accumulating data imply that HPV in the oropharynx context may still be too broad and un-specific and that it is biologically and clinically necessary to narrow down the concept of oropharynx to specific sub-sites, more specifically to tonsillar and base of tongue squamous cell carcinoma (TSCC and BOTSCC) [@bib3], [@bib4], [@bib5], [@bib6].

The oropharynx is namely a histological heterogeneous sub-site within the head and neck region that consists not only of the palatine tonsils and the base of tongue (including the lingual tonsils), but also the soft palate, the tonsillar pillars and the uvula. The histology of the palate, the pillars and the uvula is built up by a stratified squamous epithelium without a keratin layer, similar to what is observed in the oral cavity, whereas the histology of the tonsils and the tongue base is distinctly different. The tongue base and the tonsillar mucosa invaginates and forms "crypts" lined with reticulated epithelium, in which the basal lamina is discontinuous and the histological border between the epithelium and the underlying lymphoid stroma is indistinct ("lymphoepithelial tissue") [@bib7], [@bib8]. These crypts are normally not observed at the other sites of the oropharynx (or in *e.g.* oral cavity). There is now evidence demonstrating that HPV positive carcinomas develop within the histological characteristic crypts in the oropharynx, while HPV negative carcinomas emerge mainly from the surface epithelium [@bib7], [@bib8]. Due to this morphological difference in tissue tropism and absence or presence of crypts, we speculate that HPV should be evaluated per sub-site in oropharynx. Here, a systematic review is presented of literature published 2013--2016 regarding HPV prevalence per cancer sub-site in the oropharynx, and we argue that sub-site within oropharynx matters.

2. Material and methods {#s0010}
=======================

2.1. Search strategy and data extraction {#s0015}
----------------------------------------

PubMed was searched for all studies published from 2013-01-01 to 2016-10-31 using the search terms (HPV OR Papillomaviridae\[MeSH\]) AND (oropharyngeal OR oropharynx OR tonsil OR tonsillar OR "base of tongue" OR "soft palate") AND (cancer OR carcinoma) AND (2016\[DP\] OR 2015\[DP\] OR 2014\[DP\] OR 2013\[DP\]). The PRISMA statement was consulted to perform the search [@bib9]. In total 1266 articles were identified and ultimately 64 met the inclusion criteria of which 58 unique cohorts were identified and for details see the flow chart in [Fig. 1](#f0005){ref-type="fig"}. More specifically, 965 articles remained initially for further analysis after filtering out 230 as review articles, 30 not written in English, and 41 without an abstract. Abstracts from these 965 articles were then reviewed by two researchers (AN and LH) and those reporting HPV data were then further reviewed by examining the "material and method" and the "result" section in the articles. Articles reporting HPV data by a molecular tissue specific method (PCR, ISH or p16 immunohistochemistry) in HPV related "lymphoepithelial" oropharyngeal sub-sites (*i.e.* tonsillar and base of tongue) and in HPV un-related "non-lymphoepithelial" oropharyngeal sub-sites (*i.e.* walls of oropharynx, uvula and soft palate) in an un-selected cohort (retrospective/prospective, randomized/non-randomized) were included ([Fig. 1](#f0005){ref-type="fig"}). For each study, only the cohort of OPSCC patients was considered and the numbers of patients with HPV positive and negative tumours per sub-site were calculated or extracted, together with the HPV detection method. A consensus was reached for each article. The main reason for exclusion was that the sub-sites of oropharynx were not specified ([Fig. 1](#f0005){ref-type="fig"}).Fig. 1Flow diagram of study population identification and selection.Fig. 1

2.2. Statistical analysis {#s0020}
-------------------------

Differences in HPV positive and negative patient numbers were calculated by using Fisher\'s exact test (two-tailed) and Chi2-test (two-tailed) when appropriate. A p-value ≤0.05 was considered as significant. The *metan* command in Stata 11 (StataCorp, College Station, TX) was used to pool odds ratios (OR) with 95% confidence intervals (CI) across studies using the Der Simonian and Laird random-effects methods.

3. Results {#s0025}
==========

3.1. Prevalence of HPV at different OPSCC sub-sites {#s0030}
---------------------------------------------------

In total, 64 articles were included in the analysis, with a total of 11710 patients in these studies. The number of patients varied between 30 and 1474 (mean 202 patients per study) ([Table 1](#t0005){ref-type="table"}) [@bib10], [@bib11], [@bib12], [@bib13], [@bib14], [@bib15], [@bib16], [@bib17], [@bib18], [@bib19], [@bib20], [@bib21], [@bib22], [@bib23], [@bib24], [@bib25], [@bib26], [@bib27], [@bib28], [@bib29], [@bib30], [@bib31], [@bib32], [@bib33], [@bib34], [@bib35], [@bib36], [@bib37], [@bib38], [@bib39], [@bib40], [@bib41], [@bib42], [@bib43], [@bib44], [@bib45], [@bib46], [@bib47], [@bib48], [@bib49], [@bib50], [@bib51], [@bib52], [@bib53], [@bib54], [@bib55], [@bib56], [@bib57], [@bib58], [@bib59], [@bib60], [@bib61], [@bib62], [@bib63], [@bib64], [@bib65], [@bib66], [@bib67], [@bib68], [@bib69], [@bib70], [@bib71], [@bib72], [@bib73]. The sub-sites tonsils and base of tongue dominated the oropharyngeal cancer sites (83%), whereas only a minority of the tumours were located in the soft palate and the oropharyngeal walls (17%). Total oropharyngeal HPV prevalence per study varied between 7% and 88% ([Table 1](#t0005){ref-type="table"}). Notably, HPV was more commonly found in "lymphoepithelial" tissues (TSCC and BOTSCC) as compared to "non-lymphoepithelial" tissues ("other" OPSCC) of the oropharynx ([Table 1](#t0005){ref-type="table"}, [Fig. 2](#f0010){ref-type="fig"}A). Total HPV prevalence in TSCC/BOTSCC was 56%, 95% CI: 55--57% (59%, 95% CI: 58--60% for TSCC only) as compared to 19%, 95% CI: 17--20%, HPV prevalence in "other" OPSCC ([Table 1](#t0005){ref-type="table"}).Fig. 2Heat map of HPV prevalence by oropharyngeal cancer sub-site. (A) Prevalence of HPV, defined by each included study, stratified by tonsillar (TSCC) and base of tongue (BOTSCC) squamous cell carcinomas *vs*. "other" (i.e. walls of oropharynx, uvulae and soft palate) oropharyngeal squamous cell carcinomas (OPSCC). (B) Prevalence of HPV, defined by each included study, stratified by TSCC only *vs.* "other" OPSCC.Fig. 2Table 1Studies and their patients included in the meta-analysis.Table 1Author, YearCountry[a](#tbl1fna){ref-type="table-fn"}OropharyngealHPV+HPV-HPVHPVp-value[\*](#tbl1fnStar){ref-type="table-fn"}p-value[\*](#tbl1fnStar){ref-type="table-fn"}sub-sitetumourstumoursprevalencedetection(TSCC and BOTSCC *vs.*"other" OPSCC)(TSCC only *vs."*other" OPSCC)Bahl et al., 2014 [@bib10]IndiaBase of tongue146119% (18--20%)PCRNSNSTonsil101540% (36--44%)Soft palate050% (0--0%)  Bhosale et al., 2016 [@bib11]IndiaBase of tongue0230% (0--0%)p16 IHCNSNSTonsil31814% (11--18%)Soft palate050% (0--0%)Posterior wall1420% (4--36%)  Broglie et al., 2013 [@bib13]SwitzerlandBase of tongue222844% (42--46%)p16 IHCNSNSTonsil313746% (44--48%)Post wall/ soft palate1517% (4--29%)  Broglie et al., 2015 [@bib12]SwitzerlandBase of tongue3350% (34--66%)p16 IHCNSNSTonsil361373% (72--75%)Post wall020% (0--0%)  Busso et al., 2014 [@bib14]ItalyBase of tongue1109% (4--14%)PCRNSNSTonsil132138% (35--41%)Soft palate2167% (36--97%)Posterior wall020% (0--0%)  Cerezo et al., 2014 [@bib16]SpainBase of tongue103025% (23--27%)p16 IHCNSNSTonsil112729% (27--31%)Cerezo et al., 2014 [@bib15]Soft plate5838% (31--46%)Pharyngeal wall1150% (1--99%)  Dahlstrom et al., 2015 [@bib17]United States of AmericaBase of tongue1391690% (89--90%)p16 IHC and ISH with/without PCR0.040.04Tonsil1722289% (88--90%)Other4357% (43--71%)  Davis et al., 2014 [@bib18]United States of AmericaBase of tongue5456% (45--66%)p16 IHC0.0030.002Tonsil12380% (75--85%)Soft palate060% (0--0%)  Doná et al., 2015 [@bib19]ItalyBase of tongue263443% (42--45%)PCR0.0020.003Tonsil303447% (45--48%)Other oropharynx1156% (3--9%)  Evans et al., 2013 [@bib20]United KingdomBase of tongue and vallecula152043% (40--46%)p16 IHC and PCR and/or ISH0.0010.0003Tonsil543958% (57--59%)Other oropharynx0100% (0--0%)  Fahkry et al., 2014 [@bib21]United States of AmericaBase of tongue523659% (58--60%)p16 IHC0.020.002Tonsil391967% (66--69%)Soft palate030% (0--0%)Oropharynx NOS14961% (57--65%)Faucial arch010% (0--0%)Pharyngeal oropharynx080% (0--0%)  Faust et al., 2016 [@bib22]SwedenBase of tongue151256% (52--59%)PCR0.001\<0.001Tonsil752873% (72--74%)Oropharynx NOS2918% (11--25%)  Fonmarty et al., 2015 [@bib23]Not specifiedAnterior/lateral oropharynx (*tonsil, base of tongue and glossotonsillar sulcus*)203139% (37--41%)p16 IHC and PCR\<0.001--Other oropharyngeal sites0200% (0--0%)  Fujimaki et al., 2013 [@bib24]JapanLateral272354% (52--56%)p16 IHC and ISHNS0.05Anterior4736% (28--45%)Posterior030% (0--0%)Superior020% (0--0%)  Grisar et al., 2016 [@bib26]BelgiumTongue base63614% (13--16%)p16 IHCNS0.05Tonsil8753% (47--60%)Soft palate1420% (4--36%)Oropharynx NOS82624% (21--26%)  Habbous et al., 2013 [@bib27]CanadaBase of tongue1595076% (76--76%)p16 IHC\<0.0001\<0.0001Tonsil3088379% (79--79%)Other oropharynx275633% (31--34%)  Hama et al., 2014 [@bib28]JapanAnterior62023% (20--26%)PCR\<0.0001\<0.0001Lateral734462% (62--63%)Upper0100% (0--0%)Posterior040% (0--0%)  Henneman et al., 2015 [@bib29]NetherlandsBase of tongue133627% (25--28%)PCR0.0030.001Tonsil374147% (46--49%)Other oropharynx1185% (3--8%)  Hong et al., 2013 [@bib32]AustraliaBase of tongue111838% (35--41%)PCR and p16 IHC0.001\<0.001Tonsil998454% (54--55%)Other oropharynx31814% (11--18%)  Hong et al., 2014 [@bib31]AustraliaBase of tongue293049% (47--51%)PCR and p16 IHC\<0.001\<0.001Tonsil18122245% (45--45%)Other oropharynx104319% (17--20%)  Hong et al., 2013 [@bib30]AustraliaBase of tongue153133% (31--35%)PCR and p16 IHC\<0.0010.0001Tonsil25329846% (46--46%)Other oropharynx94118% (16--20%)  Isayeva et al., 2013 [@bib33]United States of AmericaBase of tongue201656% (53--58%)RT-PCRNS0.03Tonsil31978% (75--80%)Soft palate/uvula3350% (34--66%)Oropharynx101050% (45--55%)  Iyer et al., 2015 [@bib34]United States of AmericaBase of tongue503956% (55--57%)p16 IHC\<0.0001\<0.0001Tonsil481873% (71--74%)Soft palate83817% (16--19%)  Jiang et al., 2015 [@bib35]United States of AmericaBase of tongue12380% (75--85%)ISH\<0.00010.0001Tonsil10663% (57--68%)Soft palate0100% (0--0%)  Kim et al., 2014 [@bib38]Not specifiedBase of tongue51229% (24--35%)PCRNSNSTonsil153232% (30--34%)Soft palate1910% (4--16%)  Kim et al., 2015 [@bib37]South KoreaBase of tongue1325% (4--46%)p16 IHC\<0.001\<0.001Tonsil792576% (75--77%)Soft palate1811% (4--18%)Oroharynx NOS8850% (44--56%)  Kwakami et al., 2013 [@bib36]JapanBase of tongue4931% (24--38%)PCR\<0.0010.001Tonsil312952% (50--53%)Other oropharynx52616% (14--18%)  Kwon et al., 2016 [@bib39]New ZealandTonsil and tonguebase863174% (73--74%)p16 IHC\<0.0001--Other oropharynx0140% (0--0%)  Lam et al., 2015 [@bib40]ChinaBase of tongue43510% (9--12%)PCR and E6\*I mRNA0.010.003Tonsil368829% (28--30%)Soft palate3299% (8--11%)Other oropharyngeal walls0120% (0--0%)  Lee et al., 2016 [@bib41]South KoreaBase of tongue15479% (75--83%)p16 IHC\<0.0001\<0.0001Tonsil891288% (87--89%)Soft palate040% (0--0%)Posterior wall020% (0--0%)  Van Limbergen et al., 2014 [@bib70]BelgiumBase of tongue166719% (18--20%)PCR and p16IHC0.002\<0.001Tonsil337231% (31--32%)Soft palate0110% (0--0%)Pharyngeal wall1303% (2--4%)Unclear31616% (12--20%)  Liu et al., 2015 [@bib42]AustraliaBase of tongue71335% (30--40%)PCR and ISH0.002\<0.001Tonsil392957% (56--59%)Other oropharynx21512% (8--15%)  Ljokel et al., 2016 [@bib43], [@bib44]NorwayBase of tongue281368% (66--71%)PCR\<0.0001[\*\*](#tblt0005fn7876){ref-type="table-fn"}\<0.0001Tonsil863969% (68--70%)Lybak et al., 2016 [@bib45]Tonsil pillar1128% (4--12%)Overlapping tonsil10100% (100--100%)Oropharynx (ICD-10 C10)32212% (9--15%)Soft palate and overlapping lesion41029% (22--35%)Uvula1614% (4--24%)        McIlwain et al., 2014 [@bib47]United States of AmericaBase of tongue26876% (74--79%)p16 IHC0.040.02Tonsil41589% (88--90%)Soft palate4267% (51--82%)Posterior wall020% (0--0%)  Mazul et al., 2016 [@bib46]United States of AmericaBase of tongue502368% (67--70%)PCRNSNSTonsil1153378% (77--78%)Other oropharynx171063% (59--66%)  Melkane et al., 2014 [@bib48]FranceLymphoid location (*tonsillar and base of tongue*)655753% (52--54%)p16 IHC0.03--Nonlymphoid location (*posterior oropharyngeal wall and soft palate*)2918% (11--25%)  Melkane et al., 2014 [@bib49]FranceLymphoid location281368% (66--71%)p16 IHC\<0.01--Non-lymphoid location050% (0--0%)  Mizumachi et al., 2013 [@bib50]JapanLateral wall182344% (42--46%)PCRNS0.04Anterior wall41422% (18--27%)Superior wall1811% (4--18%)Posterior wall030% (0--0%)  Morbini et al., 2014 [@bib51]ItalyBase of tongue6460% (50--70%)mRNA ISH\<0.01\<0.01Tonsil13862% (57--66%)Soft palate1910% (4--16%)  Naik et al., 2015 [@bib52]United States of AmericaBase of tongue70692% (91--93%)p16 IHC and/or ISHNSNSTonsil561085% (84--86%)Other4180% (64--96%)  Nasman et al., 2013 [@bib53]SwedenBase of tongue752873% (72--74%)PCR\<0.0001\<0.0001Tonsil2176677% (76--77%)Other oropharynx42713% (11--15%)Soft palate71532% (28--36%)  Nichols et al., 2013 [@bib54]United KingdomBase of tongue151060% (56--64%)PCR\<0.010.01Tonsil312160% (58--61%)Other41422% (18--27%)  Nomura et al., 2014 [@bib55]JapanLateral wall292554% (52--56%)PCR and/or p16 IHC0.020.05Base of tongue8467% (59--74%)Superior wall070% (0--0%)Posterior wall2250% (26--74%)  Oguejiofor et al., 2013 [@bib56]United KingdomBase of tonge322754% (53--56%)p16 IHCNSNSTonsil845162% (62--63%)Other oropharynx9853% (47--595)  Ou et al., 2016 [@bib57]New ZealandBase of tongue15575% (71--79%)p16 IHC and PCR0.020.02Tonsil23485% (83--88%)Soft palate2167% (36--97%)Oropharyngeal wall010% (0--0%)Oropharynx (unspecified)1325% (4--46%)  Quabius et al., 2015 [@bib58], [@bib59]GermanyTonsillar597644% (43--44%)PCR0.030.03Soft palate and posterior wall of oropharynx31715% (12--18%)  Rietbergen et al., 2013 [@bib60]NetherlandsBase of tongue5116124% (24--24%)p16 IHC and PCR\<0.0001\<0.0001Tonsil9624828% (28--28%)Soft palate91157% (7--8%)Oropharynx NOS71225% (5--6%)  Rietbergen et al., 2013 [@bib61]NetherlandsBase of tongue135419% (18--21%)P16 IHC and PCR\<0.001\<0.0001Tonsil236028% (27--29%)Soft palate0310% (0--0%)Oropharynx NOS5548% (8--9%)  Saito et al., 2015 [@bib62]JapanLateral wall454848% (47--49%)p16 IHC0.0050.002Base of tongue122929% (27--31%)Superior wall1109% (4--14%)Posterior wall050% (0--0%)  Schache et al., 2013 [@bib64]United KingdomBase of tongue5838% (31--46%)qRT-PCRNSNSTonsil222151% (49--53%)Soft palate4931% (24--38%)Oropharynx NOS2722% (13--31%)  Schache et al., 2016 [@bib65]United KingdomBase of tongue17918349% (49--50%)p16 IHC and PCR or ISH\<0.0001\<0.0001Tonsil52832662% (62--62%)Soft palate/uvula8809% (8--10%)Oropharynx NOS4912129% (28--29%)  Schouten et al., 2016 [@bib66]Not statedBase of tongue12763% (58--68%)p16 IHC and PCRNSNSTonsil12667% (62--72%)Oropharynx NOS3443% (29--57%)  Steinau et al., 2014[b](#tbl1fnb){ref-type="table-fn"}[@bib67]United States of AmericaBase of tongue1496470% (70--70%)PCR\<0.0001\<0.0001Saraiya et al., 2015[b](#tbl1fnb){ref-type="table-fn"}[@bib63]Tonsil2014980% (80--81%)Goodman et al., 2015[b](#tbl1fnb){ref-type="table-fn"}[@bib25]Other oropharynx464849% (48--50%)  Strojan et al., 2015 [@bib68]SloveniaBase of tongue41620% (16--24%)E6/E7 mRNA ISHNS0.05Tonsil122830% (28--32%)Other oropharynx43510% (9--12%)  Tural et al., 2013 [@bib69]TurkeyBase of tongue121544% (41--48%)PCRNSNSTonsil261958% (56--60%)Other4544% (34--55%)  Wang et al., 2016 [@bib72]ChinaBase of tongue6688% (7--9%)PCRNS\<0.0001Tonsil7370% (61--79%)Soft palate3476% (5--7%)Oropharynx NOS64811% (10--12%)  Ward et al., 2014 [@bib73]United KingdomBase of tongue402859% (57--60%)p16 IHC and ISH\<0.0001\<0.0001Tonsil995763% (63--64%)Other oropharynx103622% (20--23%)  Wagner et al., 2015 [@bib71]GermanyTonsil201263% (60--65%)P16 IHC and PCR and/or ISH--\<0.0001Other than tonsil128413% (12--13%)[^1][^2][^3][^4]

Furthermore, since there is a risk of misclassification of large mobile tongue cancer into BOTSCC and vice versa, a sub-group analysis was performed comparing only TSCC and "other" OPSCC. The differences observed between "lymphoepithelial" and "non-lymphoepitelial" tissues were here even more pronounced ([Table 1](#t0005){ref-type="table"} and [Fig. 2](#f0010){ref-type="fig"}B).

In addition, a separate analysis including only studies reporting HPV prevalence data divided by tonsillar, base of tongue, soft palate/uvulae and oropharynx was performed. As depicted in [Table 2](#t0010){ref-type="table"}, HPV prevalence was highest in TSCC, followed by BOTSCC, and lower at the other sites ([Table 2](#t0010){ref-type="table"}).Table 2HPV prevalence by oropharyngeal sub-site (data extracted only from studies reporting HPV data separated by tonsils, tongue base, soft palate/uvulae and oropharyngeal walls).Table 2Oropharyngeal sub-site[a](#tbl2fna){ref-type="table-fn"}HPV+HPV-HPVtumourstumoursprevalence (95% CI)Tonsil[b](#tbl2fnb){ref-type="table-fn"}1577123856% (54--58%)Base of tongue[c](#tbl2fnc){ref-type="table-fn"}59088140% (38--43%)Soft palate[d](#tbl2fnd){ref-type="table-fn"}5942912% (9--15%)Posterior wall[e](#tbl2fne){ref-type="table-fn"}12253719% (16--22%)[^5][^6][^7][^8][^9]

3.2. HPV is significantly more prevalently found in TSCC and BOTSCC compared to other OPSCC sites {#s0035}
-------------------------------------------------------------------------------------------------

The odds ratio of having HPV in TSCC and BOTSCC as compared to "other" OPSCC was calculated and studies were grouped by HPV detection method, *i.e.* either HPV DNA PCR alone, or p16 IHC alone, or a HPV DNA based algorithm, *i.e.* combining HPV DNA and p16 overexpression. The odds having HPV in TSCC and BOTSCC as compared to "other" OPSCC was significantly higher, no matter which detection method that was used as depicted in [Fig. 3](#f0015){ref-type="fig"} (PCR: OR 4.60 95% CI 2.95--7.16, p\<0.001; p16 IHC: OR 4.26 95% CI 2.41--7.53, p\<0.001; algorithm: OR 5.19 95% CI 4.24--6.34, p\<0.001). Notably, no statistical heterogeneity (Chi^2^=8.84 (d.f.=15) p=0.885; Estimate of between-study variance Tau-squared=0.00) was observed when applying the algorithm using the presence of HPV in combination with p16 overexpression as defining positive HPV status ([Fig. 3](#f0015){ref-type="fig"}C). In contrast, when using either HPV DNA PCR positivity or p16 alone, gave significant statistical heterogenic results (PCR: Chi^2^=36.09 (d.f.=16) p=0.003; Estimate of between-study variance Tau-squared=0.39 *and* p16 IHC: Chi^2^=49.17 (d.f.=16) p\<0.001; Estimate of between-study variance Tau-squared=0.76) ([Fig. 3](#f0015){ref-type="fig"}A and B).Fig. 3Forrest plot with odds ratios (OR) of having HPV in tonsillar and base of tongue squamous cell carcinomas (TSCC and BOTSCC respectively) vs. "other" (*i.e.* walls of oropharynx, uvulae and soft palate) oropharyngeal squamous cell carcinoma (OPSCC) presented by molecular detection method. (A) OR (95% CI) of having HPV, defined by presence of HPV DNA by PCR, in TSCC/BOTSCC vs. "other" OPSCC. (B) OR (95% CI) of having HPV, defined by overexpression of p16 immunohistochemistry (IHC), in TSCC/BOTSCC vs. "other" OPSCC. (C) OR (95% CI) of having HPV, defined by an algorithm combining presence of HPV DNA and overexpression of p16 IHC, in TSCC/BOTSCC vs. "other" OPSCC.Fig. 3

4. Discussion {#s0040}
=============

In this systematic review, HPV prevalence was significantly higher in "lymphoepithelial" sites of the oropharynx, *i.e.* tonsil and base of tongue, as compared to "non-lymphoepithelial" sites of the oropharynx, *i.e.* soft palate and oropharyngeal, irrespectively of HPV detection method.

Numerous previous studies have focused on differences in HPV prevalence between different head and neck cancer sites and different geographic areas [@bib6], [@bib74], but few have addressed the relevance of sub-sites within oropharynx. As there has been a focus on OPSCC in contrast to HNSCC in general, many studies have unfortunately not specified these oropharyngeal sub-sites and very few studies have verified the sub-sites by histopathology. Recently however, Garnaes et al. [@bib4] subdivided TSCC into specified TSCC ("lymphoepithelial") and non-specified TSCC ("non-lymphoepithelial") by histomorphology. This study reported that HPV prevalence was higher and increased over time in specified TSCC, while the prevalence of HPV was lower and stable over time in non-specified TSCC. Notably, the authors also observed a significant discordant HPV DNA and p16 IHC positivity in non-specified TSCC as compared to specified TSCC. Likewise, Marklund et al. have also presented similar results with discordant p16 status and HPV DNA positivity by PCR in oropharyngeal sub-sites outside the tonsils and the tongue base [@bib5]. Analogous data have also been conveyed in oral carcinomas [@bib75]. Moreover, in a recent meta-analysis of HPV prevalence in different head and neck sites, 24.2% (18.7--30.2) of the oral carcinomas were reported to harbour HPV DNA [@bib6]. Comparable prevalence data were here described for "other" OPSCC (19%, 95% CI: 17--20%), which -- together with the overlapping histomorphology -- may suggest that"other" OPSCC are more comparable with oral carcinomas than TSCC/BOTSCC. Hence, we argue that not only geographic region and detection method should be considered when reporting HPV prevalence, but also oropharyngeal sub-site.

Studies by others have shown that HPV status defined by only p16 IHC or PCR alone in OPSCC may be too unspecific, and that if the methods are combined in an algorithm there is a high concordance with presence of active HPV infection [@bib61]. Although the odds ratios, reported in this study, of having HPV in TSCC and/or BOTSCC as compared to "other" OPSCC was higher independent of method used, there was a significant heterogeneity between studies using p16 or PCR alone. In contrast, statistical heterogeneity was not observed when uniting studies using an algorithm combining HPV DNA and p16 overexpression, which suggests that using only a PCR or p16 based HPV detection method is too unspecific and may detect false HPV positive samples in non-tonsillar non-base of tongue OPSCC.

Notably, HPV prevalence per oropharyngeal sub-site is not only of academic concern, it is in fact of clinical importance. In a recently published Danish study, patients with specified TSCC and BOTSCC had a better clinical outcome if their tumours were both HPV DNA and p16 positive as compared to being only p16 positive, while an analogous difference in clinical outcome was not observed in patients with non-specified TSCC [@bib3]. Similar results were reported by Ljokjel et al.[@bib44] In that study, patients with HPV positive TSCC and BOTSCC were reported to have a better clinical outcome, but no differences in clinical outcome were observed between patients with HPV positive and negative "other" OPSCC. Likewise, a study by Marklund et al.[@bib5] showed that HPV infection was not correlated to patient outcome if the patients had a non-tonsillar, non-base of tongue OPSCC.

Currently, it is discussed whether oncological treatment can be tapered in patients with HPV positive OPSCC, and randomized controlled studies have shown a beneficial survival in patients with HPV positive OPSCC. However, since patients with TSCC and BOTSCC dominate the OPSCC patient group, there is a risk that patients with TSCC and BOTSCC in published survival studies supersede patients with "other OPSCC". This could lead to that patients with "other OPSCC" could disfavour from the introduction of tapered treatment, as well as that de-escalated therapy could be offered to patients with HPV positive "other" OPSCC, where survival benefit is doubtful. Notably, according to the newest 8th AJCC staging system, all oropharyngeal malignancies should be staged depending on their p16 status [@bib76]. In light of data presented and discussed here, this approach could potentially be problematic. Subsequently, sub-specific survival analysis studies in oropharynx are highly warranted.

There are recognisable limitations in this study. First of all, since OPSCC still is a relatively rare disease, there is a risk that same patients are included in different studies/cohorts. To reduce this risk, we have restricted our analysis to patient cohorts included in reports published during the three last years, still allowing for the inclusion of more than 11.000 patients. We also focused on the patient cohort description in the material and method sections, but there could still be a risk for non-described overlapping patients between studies. Secondly, there is also a possibility of misclassification of tumours within the oropharyngeal region. This is especially evident in the distinction between large mobile tongue carcinomas and BOTSCC, in which only the latter is HPV associated. Relatedly, sub-coding of TSCC is infrequently presented. As stated in the introduction section, the histology and, most likely, the HPV prevalence differs between specified TSCC (ICD-10 C09.0) and *e.g.* carcinomas of the tonsillar pillars (ICD-10 C09.1). Furthermore, few studies have sub-classified OPSCC by histo-morphology [@bib4]. Nevertheless, misclassification of sub-sites would most likely only dilute the HPV prevalence numbers and thus reduce the HPV differences between TSCC/BOTSCC and "other" OPSCC. Lastly, it has been documented that HPV prevalence differs between geographic regions [@bib6] and studies included in this report are obtained from different geographical regions with different risk factors. Nonetheless, since the difference in HPV prevalence between sub-sites is studied here, and not absolute numbers, the impact of patient nationality should be minor.

To conclude, combining HPV DNA and p16 overexpression is safer for defining HPV positivity compared to using HPV DNA or p16 alone, and with this algorithm HPV was significantly more prevalent in TSCC/BOTSCC as compared to "other OPSCC sites". The clinical role of HPV in "other" OPSCC must be further evaluated before initiation of de-escalation trials in these patients.
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[^1]: p-value calculated by chi-2 test (tonsil and tongue base vs other oropharynx and soft palate; *or* tonsil vs other oropharynx and soft palate) after patient numbers had been extracted from article.

[^2]: p-value calculated by chi-2 test (tonsil and tongue base, overlapping tonsil vs tonsil pillars other oropharynx and soft palate) after patient numbers been extracted from article.

[^3]: Countries from which the patient material and data were collected.

[^4]: Patients reported in Stainau et al. presented.

[^5]: This table only presents data from studies that have divided by oropharyngeal sub-sites: base of tongue, tonsil, soft palate and posterior wall. Following studies where included: 11, 14--16, 21, 24, 26, 28, 33, 37, 40--41, 43--45, 47, 50, 53, 55, 57, 60--62, 64--65, 70, 72.

[^6]: Includes tonsil, tonsil pillar, overlapping tonsil and lateral wall.

[^7]: Includes base of tongue and anterior wall.

[^8]: Includes soft palate, uvula, superior wall, upper, and soft palate with overlapping lesion.

[^9]: Includes Posterior wall, Oropharyngeal NOS, pharyngeal wall and faucial arch.
